SUPPORTING INFORMATION

Asymmetric synthesis of (+)-isofebrifugine and (–)-sedacryptine from a common chiral non-racemic building block.

Andrew G. H. Wee* and Gao-Jun Fan Department of Chemistry and Biochemistry University of Regina, Regina Saskatchewan, Canada, S4S 0A2

Pages

Experimental procedures for compounds 10-14, (+)-1, 16-21,	
(–)- 2 , and 22	S-2 - S-10

Spectral data for compounds 10–14, (+)-1, 16, 18a,b, 19-22, (-)-2. S-11 – S-	Spectral data for	compounds 10-	-14, (+)-1, 16,	18a,b, 19-22,	(-)-2.	S-11 – S-3
--	-------------------	---------------	-----------------	---------------	--------	------------

1D NOEDY experiments on cyclic carbamate 22	S-39 – S-41
---	-------------

Preparation of compound 10

To an suspension of MePh₃P⁺ Br⁻ (0.80 g, 2.24 mmol) in THF (8 mL) at 0 °C was added *n*-BuLi (1.5 M in hexane, 1.15 mL, 1.77 mmol) dropwise. After additon was complete, an orange solution was obtained. The reacton mixture was stirred at that 0 °C for 10 min, and then lactol 9 (219 mg, 0.88 mmol) in THF (2 mL) was added via cannula. The mixture was stirred at 0 °C for 30 min and then at rt for 3 h. Saturated aqueous NH₄Cl solution (6 mL) was then added and the the organic layer was separated. The aqueous layer was re-extracted with EtOAc (x4). The combined organic layers were washed with brine, dried (Na_2SO_4), filtered and evaporated under reduced pressure. The residue was purified by flash chromatography (1:1, then 2:3 v/v pet. ether:EtOAc and finally EtOAc) to give recovered lactol 9 (20 mg), and the target alkene alcohol (145 mg, 74%).



 $\stackrel{\text{NM}}{=} IR v_{\text{max}}: 3162 - 3587, 1613 \text{ cm}^{-1}; {}^{1}\text{H NMR} (\text{CDCl}_{3}, 300 \text{ MHz}), \delta: 7.10 - 7.40 \text{ (m, 5H)}, 5.70 - 7.40 \text{ (m, 5H)}, 5.70 - 7.41 \text{ Hz} = 17.3 \text{ L} 4 \text{ Hz} = 10.4 \text{ Hz}),$ 5.82 (m, 1H), 5.30 (d, 1H, J = 15.1 Hz), 5.07 (dd, 1H, J = 17.3, 1.4 Hz), 5.02 (d, 1H, J = 10.4 Hz), 3.80–3.92 (m, 2H), 3.31 (dd, 1H, J=10.9, 5.9), 2.25–2.65 (m, 4H), 1.75–1.95 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz), δ:169.8, 137.1, 135.5, 128.6, 127.8, 127.3, 117.8, 67.0, 59.1, 48.3, 33.6, 28.5, 25.4; EI-HRMS calcd for $C_{15}H_{20}NO_2$ (MH⁺) 246.1494, found 246.1495

A solution of the above alkene alcohol (130 mg, 0.53 mmol), MOM-Cl (80 µL, 1.06 mmol), iPr₂NEt (371 µL, 2.12 mmol) and Bu₄NI (1.9 mg) in 1,2-dichloroethane was heated at reflux overnight. Upon cooling, the reaction was quenched by addition of 10 % aqueous Na₂CO₃. The reaction solution was washed with brine, dried (Na₂SO₄) and evaporated under reduced pressure. The residue was purified by flash chromatography (2:1 and then 3:2 v/v pet. ether: EtOAc) to give MOM ether 10 (139 mg, 91%) as colorless oil.



 $[\alpha]_D^{22} = -72.5^\circ$ (c 1.0, CHCl₃); IR v_{max}: 1643, 1449, 1032 cm⁻¹; ¹H NMR (CDCl₃, 300 10 MHz), δ: 7.15–7.30 (m, 5H), 5.75–5.85 (m, 1H), 5.40 (d, 1H, J = 15.1 Hz), 5.05–5.15 (m, 2H), 4.56 (d, 1H, J = 6.9 Hz), 4.52 (d, 1H, J = 6.9 Hz), 3.90 (d, 1H, J = 15.1 Hz), 3.77 (g, 1H, J = 4.8 Hz), 3.38–3.46 (m, 1H), 3.27 (s, 3H), 2.45–2.70 (m, 3H), 2.26–2.38 (m, 1H), 1.88–2.08 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz), 8: 169.4, 137.2, 135.5, 128.6, 127.8, 127.3, 117.7, 95.6, 72.9, 57.9, 55.6, 48.7, 33.9, 28.8, 23.3; EI-HRMS calcd for C₁₄H₁₈NO₃ (M–CH₂CH=CH₂) 248.1287, found 248.1295.

Preparation of compound **11**

To a solution of **10** (289 mg, 0.45 mmol) in THF (5 mL) was added LiAlH₄ (1 M in THF, 0.54 mL). The mixture was heated at reflux for 1 h, cooled at 0 °C, and the reaction was quenched by addition of 10 drops of water and 7 drops of 5 M aqueous NaOH solution. The mixture was stirred for another 20 min, at which time the suspension was filtered through a short pad of Celite[®]. The solvent was removed under reduced pressure and the residue was purified by flash chromatography (CH₂Cl₂) to give Nbenzyl piperidine derivative (114 mg, 93%) as a light yellow oil.


 $\begin{bmatrix} \alpha \end{bmatrix}_{D}^{22} = -14.2^{\circ} (c \ 1.23, CHCl_3); IR \ v_{max}: \ 1143, 1096, 1037 \ cm^{-1}; \ ^{1}H \ NMR \ (CDCl_3, 300 \ MHz), \delta: 7.20-7.32 \ (m, 5H), 5.82-5.96 \ (m, 1H), 5.06 \ (d, 1H, J = 17.1 \ Hz), 4.99 \ (d, 1H \ J = 10.0 \ Hz), 4.64 \ (s, 3H), 3.75-3.85 \ (m, 1H), 3.74 \ (s, 2H), 3.36 \ (s, 3H), 2.83-2.94 \ (m, 1H), 2.42-2.62 \ (m, 2H), 2.28-2.40 \ (m, 2H), 1.40-1.70 \ (m, 4H); \ ^{13}C \ NMR \ (CDCl_3, 75 \ MHz), \delta: 139.5, 138.2, 128.6, 128.1, 126.7, 115.4, 95.2, 74.5, 62.3, 58.2, 55.4, 46.6, 29.0, 27.1, 21.8; EI-HRMS \ calcd \ for \ C_{14}H_{20}NO_2 \ (M-CH_2CH=CH_2) \ 234.1494, \ found \ 234.1500. \end{bmatrix}$

To an ice-cold solution of the above amine (45 mg, 0.16 mmol) in 1,2-dichloroethane (3 mL) was added 1-chloroethyl chloroformate (26 μ L, 0.24 mmol). The reaction mixture was heated at reflux for 5 h, at which time the solvent was removed under reduced pressure. The residue was dissolved in methanol (3 mL) and heated at reflux for 30 min. The solvent was evaporated under reduced pressure. The crude secondary amine was dissolved in THF (2 mL) and treated with Boc₂O (52 mg) and NaHCO₃ (40 mg) in water (2 mL). The suspension was vigorously stirred for 3 h, at which time it was extracted with ethyl acetate (x3). The combined organic layer was dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was purified by flash chromatography (5:1 v/v pet. ether:EtOAc) to give *N*-Boc piperidine derivative **11** (41 mg, 92%) as a light yellow oil.

^{Boc} 11 $[\alpha]_D^{22} = +34.8^{\circ}$ (*c* 1.15, CHCl₃); IR v_{max}: 1690, 1414, 1361, 1149, 1038 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 5.66–5.83 (m, 1H), 4.93–5.11 (m, 2H), 4.69 (d, 1H, J = 6.7 Hz), 4.66 (d, 1H, J = 6.7 Hz), 3.61–3.70 (m, 1H), 3.38 (s, 3H), 2.61–2.75 (m, 1H), 2.32–2.41 (m, 2H), 1.78–1.88 (m, 1H), 1.43–1.71 (m, 5H), 1.52(s, 3H), 1.43(s, 6 H).¹³C NMR (CDCl₃, 75 MHz), δ : 155.0, 135.3, 116.5, 95.1, 85.1, 79.4, 74.2, 55.4, 28.6, 28.3, 27.4, 25.6, 24.2; EI-HRMS calcd for C₁₅H₂₈NO₄ (MH⁺) 286.2018, found 286.2020.


Preparation of compound 12

^{Boc} 12 To a solution of **11** (32 mg, 0.11 mmol) in CH₂Cl₂ (1 mL) was added 30% hydrogen peroxide (0.2 mL), MeReO₃ (MTO) (0.2 mg) and 3-cyanopyridine (4.6 mg). The suspension was vigorously stirred for 2.5 days, at which time ice water was added and extracted with CH₂Cl₂ (x3). The combined organic layers were washed with saturated aqueous CuSO₄ solution (x3), dried (Na₂SO₄), filtered and then evaporated under reduced pressure. The residue was purified by flash chromatography (5:1 v/v pet. ether:EtOAc) to give recovered **11** (8 mg), and the desired epoxide **12** (20 mg, 80% conversion) as an inseparable mixture of diastereomers. IR v_{max} : 1689, 1413, 1149, 1037 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ (two diastereomers): 4.50–4.80 (m, 3H), 3.80–4.10 (m, 1H), 3.55–3.75 (m, 1H), 3.35 (s, 3H), 2.85–3.00 (m, 1H), 2.50–2.80 (m., 2H), 2.35–2.45 (m, 1H), 1.55–1.90 (m, 4H), 1.30–1.55 (m, 2H), 1.44 (s, 9H); ¹³C NMR (CDCl₃, 75 MHz), δ (two diastereomers) :154.8, 95.2, 79.9, 74.0, 55.5, 50.5, 47.2, 46.4, 28.3, 27.7, 27.5, 25.7, 24.1; CI(NH₃)-HRMS calcd for C₁₅H₂₈NO₅ (MH⁺) 302.1967, found 302.1978. Preparation of compound 13.




¹³ To a solution of epoxide **12** (37 mg, 0.123 mmol) in methanol (1.5 mL) was added 4-hydroxyquinazoline (22 mg, 0.148 mmol) and potassium hydroxide (1.3 mg, 0.024 mmol). The reaction mixture was heated at reflux for 48 h. Upon cooling, the solvent was removed under reduced pressure. The crude oil was dissolved in CH₂Cl₂ (10 mL), washed with 1 M aqueous NaOH (x3) and brine. The organic layer was dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was purified by flash chromatography (2:1 v/v pet. ether:EtOAc and then EtOAc) to give recovered epoxide **12** (5 mg), and secondary alcohol **13** (32 mg, 68% conversion) as an inseparable diastereomeric mixture. $[\alpha]_D^{22} = +38.6^{\circ}$ (*c* 1.10, CHCl₃); IR v_{max}: 3150–3550, 1681, 1612, 1416 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ (two diastereomers): 8.20–8.35 (m, 2H), 7.68–7.78 (m, 2H), 7.45–7.53 (m, 1H), 4.66 (s, 2H), 4.55–4.70 (m, 1H), 4.33–4.55 (m, 2H), 3.80–3.90 (m, 1H), 3.65–3.80 (m, 1H), 3.54–3.65 (m, 1H), 3.36 (s, 3H), 2.62–2.80 (m, 1H), 1.77–1.95 (m, 2H), 1.60–1.77 (m, 2H), 1.44 (s, 3H), 1.36 (s, 6H), 1.20–1.60 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz), δ (two diastereomers): 161.2, 156.6, 148.1, 148.0, 134.3, 134.2, 127.4, 127.2, 127.1, 126.9, 126.7, 126.6, 95.4, 95.0, 80.9, 80.7, 77.2, 73.4, 65.4, 55.7, 55.6, 52.0, 51.8, 49.5, 38.7, 30.0, 28.7, 28.4, 28.2, 28.1, 25.7, 24.0; EI-HRMS calcd for C₂₃H₃₃N₃O₆ 447.2369, found 447.2361.

Preparation of compound 14.



^{Boc} 14 Ö To a solution of **13** (16 mg, 0.036 mmol) in CH₂Cl₂ (2 mL) was added Dess-Martin periodinane (0.3 M in CH₂Cl₂, 0.36 mL, 0.10 mmol). The mixture was stirred at rt for 2.5 h, then was quenched by addition of aqueous Na₂S₂O₃ and extracted with EtOAc (x3). The combined organic layers were washed with saturated aqueous NaHCO₃ (x2), brine, dried (Na₂SO₄), filtered and then evaporated under reduced pressure. The residue was purified by flash chromatography (1:2 v/v pet. ether:EtOAc and then EtOAc) to afford ketone **14** (14.6 mg, 92%): $[\alpha]_D^{22} = +50.0^{\circ}$ (*c* 0.60, CHCl₃); IR v_{max}: 1729, 1680, 1612, 1473, 1412, 1364 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 8.28 (dd, 1H, J = 8.4, 0.8), 8.02 (br. s, 1H), 7.68–7.80 (m, 2H), 7.49 (ddd, 1H, J = 8.1, 6.5, 1.9 Hz), 5.10–5.30 (m, 1 H), 4.85–5.05 (m, 2H), 4.68 (br. s, 2H), 3.78–3.95 (br. s, 1H), 3.74 (quint, 1H, J = 10.9, 5.6 Hz), 3.40 (s, 3H), 2.96–3.12 (m, 1H), 2.74–2.92 (m, 1H), 2.50–2.72 (m, 1H), 1.84–1.96 (m, 1H), 1.60–1.80 (m, 1H), 1.32–1.56 (m, 2H), 1.44 (s, 9H); ¹³C NMR (CDCl₃, 75 MHz), δ : 201.1, 160.9, 155.4, 148.1, 147.0, 134.3, 127.4, 127.2, 126.8, 121.9, 95.6, 80.6, 77.2, 74.2, 55.8, 53.4, 51.3. 38.5, 36.6, 28.4, 25.5, 23.8; EI-HRMS calcd for C₂₃H₃₁N₃O₆ 445.2213, found 445.2209.

(+)-Isofebrifugine (1)



^{(+)-lsofebrifugine (1)} The solution of MOM ether **14** (11 mg, 0.024 mmol) in 6 M aqueous HCl (2 mL) was heated at reflux for 2.5 h. After the reaction mixture was cooled to rt, the mixture was treated with solid Na₂CO₃ and then extracted with chloroform (x3). The combined organic layers were dried (Na₂SO₄), filtered and then evaporated under reduced pressure. The residue was purified by flash

chromatography (2:1 v/v CH₂Cl₂:MeOH) to afford isofebrifugine (1) (6.6 mg, 89%): $[\alpha]_D^{22}$ +120.8° (*c* 0.30, CHCl₃); IRv_{max}: 3100–3575, 1672, 1609, 1473 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 8.30 (dd, 1H, J = 7.8, 1.3 Hz), 8.29 (s, 1H), 7.75 (ddd, 1H, J = 8.1, 8.1, 1.4 Hz), 7.70 (dd, 1H, J = 8.1, 1.4 Hz), 7.49 (dtd, 1H, J = 8.1, 6.8, 1.5 Hz), 4.44 (d, 1H, J = 13.9 Hz), 4.15 (d, 1H, J = 13.9 Hz), 3.89 (q, 1H, J = 2.7 Hz), 3.30 (dd, 1H, J = 3.3, 3.3 Hz), 2.99 (dd, 1H, J = 11.0, 2.8 Hz), 2.54 (ddd, 1H, J = 13.2, 2.0, 13.2 Hz), 2.05–2.15 (m, 2H), 1.88 (d, 1H, J = 13.1 Hz), 1.75–1.86 (m, 1H), 1.47–1.62 (m, 2H); ¹³C NMR (CDCl₃, 75 MHz), δ : 161.5, 148.2, 148.1, 134.3, 127.5, 127.0, 126.9, 121.9, 105.4, 77.6, 55.7, 49.9, 44.5, 43.3, 26.7, 20.0; CI(NH₃)-HRMS calcd for C₁₆H₂₀N₃O₃ (MH⁺) 302.1504, found 302.1495.

Preparation of compound 16.

The bicyclic lactam lactone **6** (361 mg, 1.47 mmol) was dissolved in dry THF (20 mL) under Ar. Lawesson's reagent (328 mg, 0.81 mmol, 0.55 mol eq) was added to the solution and the mixture was refluxed. After 3 h, the recation mixture was cooled and then concentrated. The crude product was purified by chromatography, initially using 5:1 v/v CH₂Cl₂-hexane as eluent to remove the non-polar sulfur impurities and then 2:1 v/v pet. ether-EtOAc to obtain the desired thiolactam **17** (376 mg, 98 %) as a viscous pale yellow oil.


 $[\alpha]_D^{22} = +85.0^{\circ}$ (*c* 0.50, CHCl₃); IR v_{max}: 3075, 3050, 1778, 1343, 1161 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 7.25–7.38 (m, 5H), 6.10 (d, 1H, J = 14.8 Hz), 4.58 (d, 1H, J = 14.8 Hz), 4.90–4.98 (m, 1H), 4.33 (ddd, 1H, J = 8.8, 7.5, 4.3 Hz), 3.29 (ddd, 1H, J = 17.6, 3.7 Hz), 2.92 (ddd, 1H, J = 16.9, 2.4, 4.1 Hz), 2.83 (dd, 1H, J = 18.6, 9.1 Hz), 2.57 (dd, 1H, J = 18.6, 4.1 Hz), 2.20 (ddd, 1H, J = 14.5, 7.9, 3.9 Hz), 1.91 (dddd, 1H, J = 14.5, 12.5, 3.6 Hz). ¹³C NMR (CDCl₃, 75 MHz), δ : 202.0, 173.1,134.5, 129.1, 128.3, 127.9, 76.0, 56.2, 55.3, 36.6, 35.3, 24.6; EI-HRMS calcd for C₁₄H₁₅NO₂S 261.0823, found 261.0816.

16 The above thiolactam (280 mg, 1.07 mmol) was dissolved in dry MeCN (0.5 mL) under Ar. A solution of 98 % phenacyl bromide (261 mg, 1.29 mmol, 1.2 mol eq) in dry MeCN (2 mL) was added via cannula to the thiolactam solution. The reaction mixture was stirred in the dark at rt for 24 h. The reaction mixture was diluted with dry CH₂Cl₂ (5 mL). A solution of Ph3P (508 mg, 1.94 mmol) in dry CH₂Cl₂ (4 mL) was added via cannula and the mixture was stirred at rt for 15 min. Then 1-methylpiperidine (394 uL, 3.21 mmol) was added and the mixture was stirred in the dark at rt for 24 h. The reaction mixture was concentrated, toluene (10 mL) was added to the residue and the mixture was evaporated. The crude product was purified by chromatography (1:1 v/v pet. ether-EtOAc) and then 2:1 v/v EtOAc-pet. ether) to furnish the vinylogous amide 16 (249.8 mg, 67 %) as a light brown solid. mp: 56–56.5 °C; $[\alpha]_D^{22} = +104.6^\circ$ (*c* 2.70, CHCl₃); IR v_{max}: 3050, 3012,1778, 1613, 1600, 1587, 1562, 1525 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 7.59 (br d, 2H, J = 7.1 Hz), 7.18–7.44 (m, 8H), 5.88 (br. s, 1H), 4.99 (ddd, 1H, J = 7.4, 3.7, 3.7 Hz), 4.63 (d, 1H, J = 16.3 Hz), 4.39 (d, 1H, J = 16.3 Hz), 4.28 (ddd, 1H, J = 4.3, 7.9, 7.9 Hz), 4.07 (ddd, 1H, J = 18.1, 3.1, 3.1 Hz), 2.81 (dd, 1H, J = 18.3, 8.5 Hz), 2.77–2.90 (m, 1H), 2.57 (dd, 1H, J = 18.3, 4.2 Hz), 2.18 (dddd, 1H, J = 13.4, 4.2, 4.2, 4.2 Hz), 1.82– 1.95 (m, 1H), ¹³C NMR (CDCl₃, 75 MHz), δ: 189.1, 174.3.162.2, 142.2, 135.3, 131.0, 129.4, 128.4, 128.2, 127.5, 126.9, 95.3, 76.9, 57.2, 54.3, 36.1, 23.7, 21.7. EI-HRMS calcd for C₂₂H₂₁NO₃ 347.1521, found 347.1526.

Preparation of compound 18a,b.

A suspension of platinum(IV) oxide (40 mg) in ethyl acetate (20 mL) was activated by mixing with hydrogen (45 psi) in a Parr flask for 30 min. A solution of the vinylogous amide **16** (244 mg, 0.70 mmol) in ethyl acetate (30 mL) was then added to the activated catalyst and the mixture was shaken under hydrogen (45 psi) for 4 h. The mixture was filtered through Celite[®], the residue washed several times with ethyl acetate. The combined filtrates were evaporated under reduced pressure and the residue was purified by chromatography (pet. ether:EtOAc/2:1) to give 215 mg (88%) of phenyl ketone **18a** as white solid and the minor epimer **18b** (24 mg, 10%).

18a Compound **18a**: mp: $[\alpha]_D^{22} = -31.4^{\circ}$ (*c* 0.875, CH₂Cl₂); IR v_{max}: 1778, 1678, 1219, 1155 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 7.63 (br d, 2H, J = 7.3 Hz), 7.49 (br t, 1H, J = 7.3 Hz), 7.14–7.40 (m, 7H), 4.55 (ddd, 1H, J = 3.4, 3.0, 3.0 Hz), 3.78 (d, 1H, J = 17.0 Hz), 3.70 (d, 1H, J = 17.0 Hz), 3.35 (t, 1H, J = 4.1 Hz), 3.22–3.32 (m, 1H), 3.09 (dd, 1H, J = 3.9, 17.2 Hz), 2.71 (dd, 1H, J = 17.2, 8.2 Hz), 2.68 (dd, 1H, J = 16.8, 4.7 Hz), 2.52 (d, 1H, J = 16.7 Hz), 2.12–2.24 (m, 1H), 1.60–1.84 (m, 3H). ¹³C NMR (CDCl₃, 75 MHz), δ : 198.4, 176.2, 140.5, 136.7, 132.8, 128.3 128.2, 127.5, 126.63, 126.6, 78.0, 60.7, 57.3, 56.8, 43.7, 38.8, 26.5, 24.8. EI-HRMS calcd for C₂₂H₂₃NO₃ 349.1678, found 349.1669; calcd for C₁₅H₁₆NO₃ (M–PhCH₂) 258.1130, found 258.1127.



^{18b} ^{Bn} Compound **18b**: IR ν_{max}: 1772, 1672 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ: 7.67 (br d, 2H, J = 7.5 Hz), 7.44 (t, 1H, J = 7.3 Hz), 7.14–7.34 (m, 7H), 4.45–4.54 (m, 1H), 3.76 (d, 1H, J = 14.7 Hz), 3.43 (d, 1H, J = 14.4 Hz), 3.23–3.50 (m, 3H), 2.85 (dd, 1H, J = 14.0, 9.4 Hz), 2.63 (dd, 1H, J = 17.0, 2.0 Hz), 2.54 (dd, 1H, J = 17.0, 4.9 Hz), 1.75–1.98 (m, 3H), 1.25–1.38 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz), δ: 199.4, 175.9, 138.0, 136.4, 133.3, 128.7, 128.6, 128.1, 128.0, 127.5, 77.6, 55.5, 54.3, 50.5, 36.2, 34.4, 24.7, 21.3. EI-HRMS calcd for C₂₂H₂₃NO₃ 349.1678, found 349.1680;calcd for C₁₅H₁₆NO₃ (M–PhCH₂) 258.1130, found 258.1127.

Preparation of compound 19.

Palladium(II) hydroxide/C (20 wt %, 114 mg) was washed with dry ethanol (10 mL) and then suspended in fresh, dry ethanol (10 mL). Redistilled cyclohexene (3 mL) was added and the mixture was refluxed under Ar for 30 min. and then cooled. A solution of the N-benzyl piperidine **18a** (228 mg) in dry ethanol (20 mL) was added and the mixture was refluxed under Ar. After 2 h, the reaction mixture was cooled to rt and then filtered through Celite[®], and the residue washed several times with 95% ethanol. The combined filtrates were concentrated to give crude piperidine derivative (169 mg). An analytical sample was purified by chromatography (EtOAc and then 10:1 v/v EtOAc:MeOH).

 $\sum_{Ph} \sum_{H} \sum_{I=0}^{N} [\alpha]_{D}^{22} = +20.0^{\circ}, (c \ 1.25, CH_{2}Cl_{2}); IR \ v_{max}: 1772, 1678 \ cm^{-1}; {}^{1}H \ NMR \ (CDCl_{3}, 300 \ MHz), \delta: 7.89-7.96 \ (m, 2H), 7.57 \ (dt, 1H, J = 7.3, 1.3 \ Hz), 4.40 \ (ddd, 1H, J = 3.2, 3.2, 3.2 \ Hz), 7.40-7.50 \ (m, 2H), 3.67 \ (dd, 1H, J = 4.2, 3.4 \ Hz), 3.14-3.25 \ (m, 1H), 3.08 \ (dd, 1H, J = 17.6, 3.8 \ Hz), 2.99 \ (dd, 1H, J = 17.6, 8.4 \ Hz), 2.67 \ (dd, 1H, J = 16.5, 4.4 \ Hz), 2.20-2.36 \ (m, 2 \ H), 1.67-1.82 \ (m, 1H), 1.48-1.58 \ (m, 2H). {}^{13}C \ NMR \ (CDCl_{3}, 75 \ MHz), \delta: 199.2, 176.9, 136.7, 133.4, 128.6, 127.9, 76.9, 53.4, 128.6, 128.6, 128.6, 128.6, 128.6, 128.6, 128.6, 128.6, 128.6, 128.6, 128.6, 128.6, 12$

49.8, 44.9, 40.4, 26.1, 25.9. HRMS calcd for C₁₅H₁₇NO₃ 259.1208, found 259.1200.

The crude amine above (169 mg) was dissolved in CH_2Cl_2 (20 mL) and distilled water (10 mL) was added. Potassium carbonate (1.04 g, 7.53 mmol, 11.5 mol eq) was added to the biphasic mixture. The mixture was cooled to 0°C and methyl chloroformate (466 uL, 6.0 mmol, 9.2 mol eq) was added. The mixture was vigorously stirred for 22 h. Then the aqueous phase was separated and back extracted with CH_2Cl_2 . The combined CH_2Cl_2 layers were washed with water, dried, filtered and concentrated. The residual oil was purified by flash chromatography (2:1 v/v pet. ether-EtOAc and then 1:1v/v pet. ether-EtOAc) to yield the carbamate **19** (131.2 mg, 63%).

¹⁹^{CO₂Me} $[\alpha]^{29}_{D} = +47^{\circ} (c \ 1.22, CH_2Cl_2), IR \nu_{max}: 3060, 1780, 1697, 1681, 1595, 1579 cm^{-1}.$ ¹H NMR (CDCl₃, 300 MHz), δ : 7.89 (d, 2H, J = 7.5 Hz), 7.51 (t, 1 H, J = 7.4 Hz), 7.40 (t, 2H, J = 7.8 Hz), 5.01 (q, 1H, J = 8.9 Hz), 4.72 (ddd, 1H, J = 10.7, 5.6, 5.6 Hz), 3.61 (s, 3H), 4.55–4.61 (m, 1H), 3.28 (br d, 1 H, 15.5 Hz), 3.06 (dd, 1H, J = 15.5, 10.0 Hz), 2.92 (dd, 1H, J = 18.3, 9.8 Hz), 2.50 (dd, 1H, J = 18.3, 8.4 Hz), 1.68–1.93 (m, 3H), 1.55–1.62 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz), δ : 197.2, 174.2, 156.0, 136.2, 133.3, 128.6, 128.0, 76.0, 53.0, 48.8, 48.1, 43.9, 34.4, 23.3, 22.4. EI-HRMS: calcd for C₁₇H₁₉NO₅ 317.1263, found 317.1271.


Preparation oc compound 20.

A mixture of (*R*)-2-methyl-CBS-oxazaborolidine (1.0 M in toluene, 247 μ L, 0.247 mmol, 0.6 mol eq) and BH₃.SMe₂ complex (1.67 M in ether, 148 μ L, 247 mmol, 0.6 mol eq) in dry THF (4 mL) was cooled to -40 °C, under Ar. A solution of the keto lactone **19** (131 mg, 0.413 mmol) in dry THF (3 mL) and was added via cannula and the reaction mixture was stirred at -40 °C for 50 min. Saturated NH₄Cl (1 mL) was added at -40 °C and the reaction mixture was allowed to warm slowly to rt. Brine (5 mL) and EtOAc (10 mL) were added and the mixture was stirred. The aqueous phase was separated and re-extracted with EtOAc (2 x 10 mL). The combined organic phases were washed with brine, dried, filtered and concentrated. The crude oil was purified by chromatography (1:1 v/v pet. ether-EtOAc) to afford the alcohol (113.6 mg, 86 %).

¹⁵ (R = Me) $[\alpha]_D^{29.5} = -2.79^{\circ}$ (c 2.68, CH₂Cl₂). IR v_{max}: 3589–3307, 3048, 1778, 1736, 1689 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz), δ : 7.05–7.07 (m, 5H), 5.04 (q, 1H, J = 9.0 Hz), 4.74–4.83 (m, 2H), 4.34–4.43 (m, 1H), 2.87 (dd, 1H, J = 18.3, 9.7 Hz), 2.49 (dd, 1H, J = 18.3, 9.0 Hz), 2.10 (ddd, 1H, J = 13.9, 9.8, 4.0 Hz), 1.85–1.97 (m, 4H), 1.67–1.75 (m, 1H), 1.58–1.65 (br s, 1H). EI-HRMS: calcd for C₁₇H₂₁NO₅ 319.1420, found 319.1416.

The above secondary alcohol (113 mg, 0.356 mmol) was dissolved in dry CH_2Cl_2 (3 mL) under Ar. 2,6-Lutidine (174 µL, 1.49 mmol, 4.2 mol eq) was added. The mixture was cooled to -10 °C. Then TBSOTf (163 µL, 0.712 mmol, 2 mol eq) was added dropwise to the mixture. After addition is complete, the reaction mixture was stirred at -10 °C for 15 min and then at 0 °C for 30 min. Then saturated NaHCO₃ (2 mL) was added followed by CH_2Cl_2 (10 mL). The mixture was stirred and the aqueous was separated and back extracted with CH_2Cl_2 (2 x 5 mL). The combined CH_2Cl_2 layers were washed with 0.5 N aqueous H_2SO_4 (2 x 5 mL), water and saturated NaHCO₃. The organic extract was

dried, filtered and concentrated to give an oil. Purification by chromatography (2:1 v/v pet. ether-EtOAcgave the TBS ether **20** (153 mg, 100 %).




20 $[\alpha]_D^{24} = -20.6^{\circ} (c \ 1.34, CH_2Cl_2)$. IR v_{max} : 3062, 3029, 1784, 1700 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz), δ : 0.06, 0.00 and -0.25 (s, 6H), 0.88 (s, 9H), 1.62–1.85 (m, 5H), 2.04 (ddd, 1H, J = 13.1, 8.6, 2.7 Hz), 2.34 (dd, 1H, J = 18.2, 9.0 Hz), 2.83 (dd, 1H, J = 18.2, 9.8 Hz), 3.65 (s, 3H), 4.17–4.27 (m, 1H), 4.64–4.72 (m, 2H), 5.00 (q, 1H, J = 9.1 Hz), 7.20–7.30 (m, 5H). ¹³C NMR (CDCl₃, 75 MHz), δ : 174.2, 156.1, 144.1, 128.1, 127.3, 125.7, 76.0, 72.3, 52.8, 48.6, 47.9, 46.0, 33.9, 25.6, 23.2, 21.9, 18.0, -3.7, -4.7, -5.3. CI(NH₃)-HRMS: calcd for C₂₃H₃₉N₂O₅Si (M+NH₄) 451.2628, found 451.2633.

Preparation of compound 21.

The bicyclic lactone **20** (154.2 mg, 0.356 mmol) was dissolved in dry toluene (9 mL) under Ar, and dry pyridine (0.5M in toluene, 3.56 mL, 1.78 mmol, 5 mol eq) was added. Cl_2TiMe_2 (0.2 M in toluene, 1.07 mmol, 5.35 mL, 3 mol eq) was added and the mixture was heated in an oil bath at 90 °C. After 1.5 h, the reaction mixture was cooled and a mxture of 2:1 v/v pet. ether-EtOAc containing 1 % Et₃N (10 mL) was added. The reaction mixture was filtered through a short pad of silica gel-60. The residue was washed several times with 2:1 v/v pet. ether-EtOAc containing 1 % Et₃N, and the combined filtrates were evaporated. The residual oil was dried under high vacuum for 10 min and then redissolved, under Ar, in dry MeOH. PPTS (10 mg) was added and the mixture was stirred for 4 h at rt. Et₃N (1 mL) was added, the reaction mixture was concentrated and the residue purified by chromatography (4:1 v/v pet. ether-EtOAc) to furnish the cyclic ketal (92.1 mg, 57 %) as a mixture of anomers [6:1 based on integration of the ketal OMe siglet at δ 3.18 (major) and 3.24 (minor)].

 $\sum_{CO_2Me} \sum_{N=0}^{N} \sum_{max} (D_2Me)^{N} = \frac{1}{2} \sum_{max} (D$

A solution of the above cyclic ketal (92 mg, 0.198 mmol) in dry THF (5 mL) was transferred via cannula, under Ar, to a suspension of LiAlH₄ (75 mg, 1.99 mmol, 10 mol eq) in dry THF (4 mL). The mixture was refluxed for 16 h. The reaction mixture was cooled to rt and then at 0 °C. Aqueous 10 % NaOH was added dropwise to destroy unreacted LiAlH₄ and until all aluminum salts redissolved. Celite was added to the mixture and then CH_2Cl_2 (20 mL). The mixture was stirred for 30 min and then suction filtered. The residue was washed with CH_2Cl_2 (2 x 10 mL), and the combined filtrates were dried, filtered and concentrated. The crude product was purified by chromatography (3:1 v/v pet. ether-EtOAc) to yield the amine **21** (61.5 mg, 74 %).



^{Me} ²¹ IR v_{max} : 3060, 3028 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz), δ : 7.20–7.35 (m, 5H), 4.68 (dd, 1H, J = 9.4, 2.6 Hz), 4.00–4.08 (m, 1H), 3.21 (s, 3H), 2.58–2.66 (m, 1H), 2.05–2.21 (m, 3H), 2.09 (s, 3H), 1.82–1.95 (m, 1H), 1.55–1.70 (m, 3H), 1.46 (s, 3H), 0.86 (s, 9H), 0.05, 0.00 and -0.27 (s, 6H).


¹³C NMR (CDCl₃, 75 MHz), δ: 145.9, 128.0, 126.9, 125.7, 107.1, 76.1, 72.4, 65.6, 58.6, 48.6, 46.3, 45.6, 40.1, 25.7, 24.6, 22.6, 18.0, 1.2, -4.1, -4.5. EI-HRMS: calcd for C₂₄H₄₁NO₃Si 419.2856, found 418.2864.

(–)-Sedacryptine (2)


A solution of the cyclic ketal amine **21** (58.6 mg, 0.139 mmol) in dry THF (2 mL) was treated with Bu₄NF (1 M in THF, 167 μ L, 0.167 mmol, 1.2 mol eq) at 0 °C, under Ar. The mixture was then stirred at rt for 2.5 h, concentrated and the residue was subjected to chromatography (15:1 v/v EtOAc-MeOH) to give the secondary alcohol (52.6 mg), which was immediately mixed with 0.1 M aqueous HCl (2 mL) and then reluxed for 30 min. The mixture was cooled to rt and then at 0 °C and was treated with 28 % NH₄OH to pH 9. The mixture was extracted with CH₂Cl₂ (2 x 10 mL) and the combined extracts were dried, filtered and concentrated. The residue was filtered through a short pad of silica gel-60 and using 10:1 v/v CH₂Cl₂-MeOH as solvent. The filtrate was concentrated and the residual oil was taken dissolved in MeOH and left to stand, in the dark, overnight (36 h). Then MeOH was evaporated and the residue was purified by chromatography (10:1v/v EtOAc-MeOH) to furnish (–)-sedacryptine (23.5 mg, 57.7 %).

^{(h)-2} mp (cyclohexane): 123–125 °C; lit.^{19d} mp (cyclohexane): 122–123 °C. $[\alpha]_D^{25} = -13.5$ ° (*c* 0.74, CHCl₃). IR v_{max}: 3530–3201, 3048 cm⁻¹. ¹H NMR (CDCl₃, 300 MHz), δ : 7.20–7.35 (m, 5H), 6.60–6.80 (br s, 1H), 4.81 (dd, 1H, J = 10.1, 2.8 Hz), 4.04 (q, 1H, J = 2.9 Hz), 2.67 (t, 1H, 3.5 Hz), 2.25 (s, 3H), 2.23–2.35 (m, 2H), 2.20 (d, 1H, J = 13.2 Hz), 2.16 (ddd, 1H, J = 13.6, 10.2, 2.8 Hz), 2.05 (ddd, 1H, J = 13.6, 6.8, 1.8 Hz), 1.88 (dd, 1H, J = 13.2, 3.9 Hz), 1.77–1.85 (m, 2H), 1.48–1.62 (m, 2H), 1.45 (s, 3H). ¹³C NMR (CDCl₃, 75 MHz), δ : 145.2, 128.6, 127.6, 125.5, 105.0, 76.9, 71.1, 65.5, 59.7, 44.3, 43.5, 39.7, 26.5, 25.5, 24.8. EI-HRMS: calcd for C₁₇H₂₃NO₂ (M–H₂O) 273.1729, found 273.1728.

Preparation of cyclic carbamate 22.




(from 18a) CH_2Cl_2 (4 mL) was added K₂CO₃ (140 mg, 1.02 mmol) in water (2 mL) and 1-chloroethyl chloroformate (44 µL, 0.41 mol). The suspension was vigorously stirred at rt for 2 h. Organic layer was separated and aqueous layer was extracted with CH₂Cl₂ (x3). Combined organic layers were washed with brine, dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was purified by flash chromatography (1:1 v/v pet. ether:EtOAc) to give the keto carbamate (58 mg, 96%) as a white solid and as a mixture of diastereomers. mp: 55–56 °C; $[\alpha]_D^{24} = +27.4^\circ$ (*c* 1.55, CH₂Cl₂); IR v_{max}: 1778, 1713, 1678, 1407, 1372, 1296, 1096 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ (two diastereomers): 7.92–8.00 (m, 2H), 7.54–7.62 (m, 1H), 7.42–7.52 (m, 2H), 6.57 (sextet, 1H, J = 5.8 Hz), 4.98–5.12 (m, 1 H), 4.76–4.86 (m, 1H), 4.60–4.76 (m, 1H), 3.43 (dd, 1H, J = 15.9, 3.2 Hz), 3.17 (dt, 1H, J = 15.9, 9.5 Hz), 3.02 (dd, 1H, J = 18.3, 9.7 Hz), 2.58 (dt, 1H, J = 18.3, 8.1 Hz), 1.60–2.06 (m, 7H). ¹³C NMR (CDCl₃, 75 MHz), δ : (major epimer) 196.9, 173.8, 153.0, 136.2, 133.6, 128.7, 128.1, 83.2, 75.9, 49.1, 48.3, 43.7, 34.6, 25.2, 23.1, 22.3; δ (minor epimer): 196.8, 173.8, 152.9, 136.2, 133.6, 128.7, 128.1, 83.2, 75.8, 49.1, 48.5, 44.2, 34.5, 25.1, 23.4, 22.5; EI-HRMS calcd for C₁₈H₂₀ClNO₅ 365.1030, found 365.1031.





To a solution of phenyl ketone (14.5 mg, 0.04 mmol) in THF (2 mL) at -35 °C was added (R)-2-methyl-CBS-oxazaborolidine (1.0 M in toluene, 75 µL, 0.075 mmol) and BH₃.SMe₂ complex in ether (5.0 M, 24 µL, 0.024 mmol). It was stirred at -35 °C for 30 min and then reaction mixture was quenched by addition of water and diluted with EtOAc. Organic layer was separated and aqueous layer was extracted with EtOAc (x3). The combine organic layers were washed with brine, dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was submitted to flash (1:1 v/v pet. ether:EtOAc) to give 14 mg of secondary alcohol. The secondary alcohol was dissolved in methanol (2 mL) and heated at reflux for 40 min. Upon cooling to rt, the reaction mixture was stirred with 150 mg of Amberlite resin IR-45 (OH) for 30 min. The resin was filtered off, washed twice with methanol and the combined filtrates were evaporated under reduced pressure. The residue was purified by flash chromatography (2:1 and then 1:1 v/v CH₂Cl₂:acetone) to give the amino alcohol (8.5 mg, 82%): $[\alpha]_D^{23} = -76.7^\circ$ (c 0.88, CH₂Cl₂); IR v_{max}: 3318 (br.), 1772, 1155 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 7.20–7.40 (m, 5H), 4.90 (dd, 1H, J = 10.2, 2.9 Hz), 4.35 (ddd, 1H, J = 4.0, 4.0, 3.0 Hz), 3.62 (dd, 1H, J = 5.4, 3.0 Hz), 3.06 (br. s, 2H), 2.86 (dddd, 1H, J = 13.9, 9.7, 2.5, 2.5 Hz), 2.79 (dd, 1H, J= 13.7, 5.4 Hz), 2.35 (d, 2H, J = 17.1 Hz), 1.70–1.90 (m, 2H), 1.46– 1.68 (m, 2H), 1.26–1.43 (m, 1H). ¹³C NMR (CDCl₃, 75 MHz), δ: 176.2, 144.5, 128.4, 127.4, 125.6, 76.3, 75.0, 55.2, 53.7, 45.0, 39.0, 26.5, 26.0. EI-HRMS calcd for C15H19NO3 261.1365, found 261.1362.


² To a solution of amino alcohol **9** (8 mg, 0.031 mmol) in


CH₂Cl₂ (3 mL) at -78 °C was added Et₃N (6 µL) and triphogene (12 mg, 0.04 mmol) in CH₂Cl₂ (1 mL) via cannula. The reaction mixture was stirred at -78 °C for 1 h and then was quenched by addition of saturated aqueous NaHCO₃ solution. The cold bath was removed and the reaction temperature was allowed towarm slowly to rt. The organic layer was separated and the aqueous phase was extracted with CH₂Cl₂ (x3). The combined organic layers were washed with brine, dried (Na₂SO₄), filtered and evaporated under reduced pressure. The residue was was purified by flash chromatography (2:1 then 1:1 v/v pet. ether: EtOAc and finally EtOAc) to give 5.5 mg (63%) of the cyclic carbamate. [α]_D²² = -11.1° (*c* 0.225, CHCl₃); IR v_{max}: 1778, 1689, 1407 cm⁻¹; ¹H NMR (CDCl₃, 300 MHz), δ : 7.30–7.42 (m, 5H), 5.37 (dd, 1H, J = 12.0, 3.8 Hz), 4.79–4.84 (m, 1H), 4.27 ("t", 1H, J = 5.8 Hz), 3.51–3.62 (m, 1H), 3.27 (d, 1H, J = 18.9 Hz), 3.07 (dd, 1H, J = 18.9, 6.4 Hz), 2.29–2.38 (m, 1H), 2.24 (ddd, 1H, J = 13.8, 3.8, 2.5 Hz), 2.04 (ddd, 1H, J = 13.7, 11.7, 11.2 Hz), 1.70–1.82 (m, 3H). ¹³C NMR (CDCl₃, 75 MHz), δ : 175.6, 154.3, 138.8, 128.71, 128.67, 125.4, 79.2, 76.5, 53.5, 53.2, 39.8, 38.2, 24.6, 24.2. EI-HRMS calcd for C₁₆H₁₇NO₄ 287.1158, found 287.1159.













































































TBSO H Se 2 ĉ OMe Me

무

